HomeIntersect ENT

Intersect ENT

CMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402: Publishes an ASP Clarifying Payment and Easing Payer Coverage Adjudication

CMS’s recent decisions will also clearly differentiate coding for SINUVA and PROPEL, two very different products. This will serve to simplify and streamline coding and reimbursement across our portfolio and will support evidence-based and cost-effective care across the continuum of need in chronic rhinosinusitis.

New Straight Delivery System Packaged with the PROPEL® Mini Sinus Implant Launches: Reports Intersect ENT

Intersect ENT announces U.S. availability of the new Straight Delivery System (“SDS”) packaged with the company’s PROPEL® Mini (mometasone furoate) Sinus Implant.

CMS Approves Coding Application for PROPEL Sinus Implant: Approval Establishes New S Code for PROPEL to Facilitate Specific Coding & Payment

“CMS’s agreement, at our request, to assign separate codes to SINUVA and PROPEL reflects and supports our deliberate strategy to leverage Intersect ENT’s proprietary drug-eluting sinus stent technology platform while, at the same time, broadening our portfolio of therapeutic offerings, clinical indications, and health economic data to support evidence-based and cost-effective care across the continuum of need in chronic rhinosinusitis,” notes Thomas A. West, President and CEO of the company.

CMS Approves SINUVA® Sinus Implant for Reimbursement with New C-Code and Pass-Through Payment Status

SINUVA is a non-surgical, corticosteroid-eluting implant for the treatment of nasal polyps in adult patients who have had ethmoid sinus surgery.

Intersect ENT Announces Launch of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps

4/2/18: The new treatment is clinically proven to reduce polyps and symptoms of nasal congestion.

Intersect ENT Announces FDA Approval of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps

12/11/17: Intersect ENT, Inc. today announced that it has received approval from the U.S. Food and Drug Administration for the SINUVA™ (mometasone furoate) Sinus Implant, a new targeted approach to treating recurrent nasal polyp disease in patients who have had previous ethmoid sinus surgery.

Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant Announced by Intersect ENT

Intersect ENT, Inc. (NASDAQ: XENT), announced presentation of a meta-analysis from two randomized studies evaluating the safety and efficacy of SINUVA™, an investigational steroid releasing sinus implant. The two studies evaluated the sinus implant in patients with recurrent...

Intersect ENT Announces PDUFA Date for Office-Based SINUVA™ Steroid Releasing Sinus Implant

Lisa Earnhardt, president and CEO of Intersect ENT, “The SINUVA implant offers the potential to provide a less invasive and more cost-effective solution, performed easily in the doctor’s office, for patients suffering from persistent chronic sinusitis.  She went...